Annual report pursuant to Section 13 and 15(d)

Investments in unconsolidated entities - Additional Information (Detail)

v2.4.0.6
Investments in unconsolidated entities - Additional Information (Detail) (USD $)
12 Months Ended
Jun. 30, 2012
Jun. 30, 2011
Jun. 30, 2010
Investments in and Advances to Affiliates [Line Items]      
Other than temporarily impaired and written off investment $ 3,254,000 $ 0 $ 0
Distribution received 463,000 0 50,000
Nephromics, LLC
     
Investments in and Advances to Affiliates [Line Items]      
Percentage of Investment in equity interest 16.80%    
Other than temporarily impaired and written off investment 2,400,000    
Distribution received 421,000    
Net investment under equity method 505,000.0 3,700,000  
Hemerus Medical, LLC
     
Investments in and Advances to Affiliates [Line Items]      
Percentage of Investment in equity interest 6.90%    
Net investment under equity method 551,000 773,000  
ACTGen, Inc.
     
Investments in and Advances to Affiliates [Line Items]      
Other than temporarily impaired and written off investment 854,000    
Ownership percentage on a cost basis 13.60%    
Net investment on a cost basis   $ 925,000